Document is current
Any future updates will be listed below
-
Authors
Bogers, Saskia J. https://orcid.org/0000-0003-0436-6782
Schim van der Loeff, Maarten F.
Davidovich, Udi
Boyd, Anders
van der Valk, Marc
Brinkman, Kees
de Bree, Godelieve J.
Reiss, Peter
van Bergen, Jan E. A. M.
Geerlings, Suzanne E.
,
van Bergen, J. E. A. M.
Brokx, P.
Deug, F.
Heidenrijk, M.
Prins, M.
Reiss, P.
van der Valk, M.
de Bree, G. J.
Brokx, P.
Davidovich, U.
Geerlings, S. E.
Hoornenborg, E.
Oomen, A.
van Sighem, A.
Zuilhof, W.
Schat, N.
Achterbergh, R. C. A.
van Agtmael, M.
Ananworanich, J.
Van de Beek, D.
van den Berk, G. E. L.
Bezemer, D.
van Bijnen, A.
Blok, W. L.
Bogers, S.
Bomers, M.
Boucher, C. A. B.
Brokking, W.
Burger, D.
Brinkman, K.
Brinkman, N.
de Bruin, M.
Bruisten, S.
Coyer, L.
van Crevel, R.
Daans, C. G.
Dellemann, L.
Dijkstra, M.
van Duijnhoven, Y. T.
van Eeden, A.
Elsenburg, L.
van den Elshout, M. A. M.
Ester, C.
Ersan, E.
Felipa, P. E. V.
Frissen, P. H. J.
Geijtenbeek, T. B. H.
Godfried, M. H.
van Gool, J.
Goorhuis, A.
Groot, M.
Hankins, C. A.
Heijnen, A.
Hillebregt, M. M. J.
Hogewoning, A.
Hommenga, M.
Hovius, J. W.
Janssen, Y.
de Jong, K.
Jongen, V.
Kootstra, N. A.
Koup, R. A.
Kroon, F. P.
van de Laar, T. J. W.
Lauw, F.
van Leeuwen, M. M.
Lettinga, K.
Linde, I.
Loomans, D. S. E.
van der Meer, J. T.
Mouhebati, T.
Mulder, B. J.
Mulder, J.
Nellen, F. J.
Nijsters, A.
Nobel, H.
Oostvogel, P.
Op de Coul, E. L. M.
Peters, E.
Peters, I. S.
van der Poll, T.
Ratmann, O.
Rokx, C.
van Rooijen, M. S.
van der Loeff, M. F. Schim
Schouten, W. E. M.
Sonder, G. J.
Veenstra, J.
Verbon, A.
Verdult, F.
de Vocht, J.
de Vries, H. J.
Vrouenraets, S.
van Vugt, M.
Wiersinga, W. J.
Wit, F. W.
Woittiez, L. R.
Zaheri, S.
Zantkuijl, P.
van Zelm, M. C.
Żakowicz, A.
Zimmermann, H. M. L.
-
Funding
Funding for this research was provided by:
Aids Fonds (P-42702)
H-TEAM initiative (Aids Fonds (grant number: 2013169), Stichting Amsterdam Dinner Foundation, Bristol-Myers Squibb International Corp. (study number: AI424-541), Gilead Sciences Europe Ltd (grant number: PA-HIV-PREP-16-0024), Gilead Sciences (protocol numbers: CO-NL-276-4222, CO-US-276-1712), Janssen Pharmaceutica (reference number: PHNL/JAN/0714/0005b/1912fde), M.A.C AIDS Fund, ViiV Healthcare (PO numbers: 3000268822, 3000747780) and ZonMw (grant number: 522002003).)
- License Information
-
More Information
Article History
Received: 10 December 2020
Accepted: 14 May 2021
First Online: 2 June 2021
Declarations
:
: The Medical Ethics Committee of the Amsterdam University Medical Centers, University of Amsterdam (Amsterdam UMC-AMC) determined that this study does not meet the definition of medical research involving human subjects as specified in Dutch law. Local feasibility was assessed and established by the Board of Directors in all study hospitals. All patients are given the opportunity to object to the consultation of their medical records and the use of their data for the purpose of this study through an opt-out procedure. All physicians participating in the questionnaires and interviews are asked for their content to participate in this study.
: Not applicable.
: AB is a member of the editorial board of BMC infectious diseases. All other authors declare that they have no competing interests directly related to this study.
